PTO/SB/08 (04-03)

						Sheet 1 of 1
Form PTO 1449			Docket Number 033136119	Application Number 09/541,033		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Inventor(s) Richard G. MILLER and Brian RABINOVICH		
(Use several sheets if necessary)				Filing Date March 31, 2000 Group Art Unit 1		644
JUL 0 8 2	uma		•	Mailing Date June 7, 2003	Examiner Name	J-H-ROBER NOLAN
U.S. PATENT DOCUMENTS						
Evenine	Ref.	Document Date	Document No.	Name		Filing Date If
Examiner Initials	No.	(MM/DD/YYYY)	Document No.	Ivanic		Appropriate
PN	1.	11/06/1990	4,968,483	Müller et al.		4
Examiner Initials	Ref. No.	Publication Date (MM/DD/YYYY)	Document No.	ENT DOCUMENTS Country	Translation YES NO	
PN	2.	02/26/1998	WO 98/07436	WIPO		
Examiner Initials	itials No.					
PN	3.	Åkerlund, K. et al., (January 1999) "Anti-Inflammatory Effects of a New Tumour Necrosis Factor-Alpha (TNF-α) Inhibitor (NCI-1493) in Collagen-Induced Arthritis (CIA) in Rats," Clin. & Exp. Immunol. 115(1):32-41.				
1	4.	Morrow, J. K. (January 15, 1997) "Companies Take Broad Range of Approaches to Develop Rheumatoid Arthritis Therapies," <i>Genetic Engineering News</i> Volume 17, Number 2, pp. 1, 7, 26.				
	5.	Pearson, C. M. (1956) "Development of Arthritis, Periarthritis and Periostitis in Rats Given Adjuvants," <i>Proc. Soc. Exp. Biol. Med.</i> 91(1):95-101.				
	6.	Ross, S. E. et al., (December 15, 1997) "Suppression of TNF-α Expression, Inhibition of Th1 Activity, and Amelioration of Collagen-Induced Arthritis by Rolipram," <i>J. Immunol.</i> 159(12):6253-6259.				
<i>\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</i>	7.	Terato, K. and Reife, R. A. (May 7, 2002) "A Novel Model of Arthritis Induced With Monoclonal Antibodies to Type II Collagen," <i>Stratagene Internet Website</i> located at http://www.stratagene.com/vol11_2/p56-57.htm visited on May 7, 2002, 3 pages.				
EXAMI	- fa	trick of NO Ca		DATE CONSIDERED: /0/20/03		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						
pa- 801086PTO/SB/ 08 (04-03) Patent and Trademark Office; U.S. DEPARTMENT OF COMME						NT OF COMMERCE